282 related articles for article (PubMed ID: 36545708)
1. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective.
Xie D; Shi J; Zhou J; Fan J; Gao Q
Clin Mol Hepatol; 2023 Apr; 29(2):206-216. PubMed ID: 36545708
[TBL] [Abstract][Full Text] [Related]
2. A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights.
Xie DY; Zhu K; Ren ZG; Zhou J; Fan J; Gao Q
Hepatobiliary Surg Nutr; 2023 Apr; 12(2):216-228. PubMed ID: 37124695
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Taiwan perspective.
Su TH; Wu CH; Liu TH; Ho CM; Liu CJ
Clin Mol Hepatol; 2023 Apr; 29(2):230-241. PubMed ID: 36710607
[TBL] [Abstract][Full Text] [Related]
4. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights.
Xie DY; Ren ZG; Zhou J; Fan J; Gao Q
Hepatobiliary Surg Nutr; 2020 Aug; 9(4):452-463. PubMed ID: 32832496
[TBL] [Abstract][Full Text] [Related]
5. Argentinian clinical practice guideline for surveillance, diagnosis, staging and treatment of hepatocellular carcinoma.
Piñero F; Tanno M; Aballay Soteras G; Tisi Baña M; Dirchwolf M; Fassio E; Ruf A; Mengarelli S; Borzi S; Fernández N; Ridruejo E; Descalzi V; Anders M; Mazzolini G; Reggiardo V; Marciano S; Perazzo F; Spina JC; McCormack L; Maraschio M; Lagues C; Gadano A; Villamil F; Silva M; Cairo F; Ameigeiras B;
Ann Hepatol; 2020; 19(5):546-569. PubMed ID: 32593747
[TBL] [Abstract][Full Text] [Related]
6. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.
Hui RW; Mak LY; Cheung TT; Lee VH; Seto WK; Yuen MF
Clin Mol Hepatol; 2023 Apr; 29(2):217-229. PubMed ID: 36577426
[TBL] [Abstract][Full Text] [Related]
8. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China.
Gong H; Ong SC; Li F; Weng Z; Zhao K; Jiang Z
Cost Eff Resour Alloc; 2023 Mar; 21(1):20. PubMed ID: 37004046
[TBL] [Abstract][Full Text] [Related]
11. Changes in therapeutic options for hepatocellular carcinoma in Asia.
Ogasawara S; Koroki K; Kanzaki H; Kobayashi K; Kiyono S; Nakamura M; Kanogawa N; Saito T; Kondo T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Kato N
Liver Int; 2022 Aug; 42(9):2055-2066. PubMed ID: 34780081
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
Su D; Wu B; Shi L
JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Rimini M; Rimassa L; Ueshima K; Burgio V; Shigeo S; Tada T; Suda G; Yoo C; Cheon J; Pinato DJ; Lonardi S; Scartozzi M; Iavarone M; Di Costanzo GG; Marra F; Soldà C; Tamburini E; Piscaglia F; Masi G; Cabibbo G; Foschi FG; Silletta M; Pressiani T; Nishida N; Iwamoto H; Sakamoto N; Ryoo BY; Chon HJ; Claudia F; Niizeki T; Sho T; Kang B; D'Alessio A; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimur T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Naganuma A; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Pedica F; De Cobelli F; Ratti F; Aldrighetti L; Kudo M; Cascinu S; Casadei-Gardini A
ESMO Open; 2022 Dec; 7(6):100591. PubMed ID: 36208496
[TBL] [Abstract][Full Text] [Related]
14. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination.
Tella SH; Kommalapati A; Mahipal A; Jin Z
Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740326
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma.
Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS
Nat Rev Dis Primers; 2021 Jan; 7(1):6. PubMed ID: 33479224
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options for hepatocellular carcinoma.
Eugen K
Klin Onkol; 2020; 33(Supplementum 3):20-25. PubMed ID: 33213161
[TBL] [Abstract][Full Text] [Related]
17. Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Benson AB; D'Angelica MI; Abbott DE; Anaya DA; Anders R; Are C; Bachini M; Borad M; Brown D; Burgoyne A; Chahal P; Chang DT; Cloyd J; Covey AM; Glazer ES; Goyal L; Hawkins WG; Iyer R; Jacob R; Kelley RK; Kim R; Levine M; Palta M; Park JO; Raman S; Reddy S; Sahai V; Schefter T; Singh G; Stein S; Vauthey JN; Venook AP; Yopp A; McMillian NR; Hochstetler C; Darlow SD
J Natl Compr Canc Netw; 2021 May; 19(5):541-565. PubMed ID: 34030131
[TBL] [Abstract][Full Text] [Related]
18. Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review.
Cappuyns S; Corbett V; Yarchoan M; Finn RS; Llovet JM
JAMA Oncol; 2024 Mar; 10(3):395-404. PubMed ID: 37535375
[TBL] [Abstract][Full Text] [Related]
19. Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states.
Wen F; Zheng H; Zhang P; Liao W; Zhou K; Li Q
Liver Int; 2021 May; 41(5):1097-1104. PubMed ID: 33556230
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy.
Sekiguchi S; Tsuchiya K; Yasui Y; Inada K; Kirino S; Yamashita K; Hayakawa Y; Osawa L; Higuchi M; Takaura K; Maeyashiki C; Kaneko S; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Kurosaki M; Izumi N
Cancer Rep (Hoboken); 2022 Nov; 5(11):e1613. PubMed ID: 35302279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
